NCT00749775 (ESSENCE) is a clinical trial of Selara in Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

Who is sponsoring NCT00749775?

NCT00749775 is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

What drugs are being tested in NCT00749775?

Interventions in NCT00749775: Selara.

What condition does NCT00749775 study?

NCT00749775 studies Hypertension.

Is NCT00749775 still recruiting?

NCT00749775 is currently completed. Last updated 19 December 2020.

Are results published for NCT00749775?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-12-19 · How we verify

NCT00749775: ESSENCE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eplerenone Observational Study Of Safety And Efficacy Evaluation To Normalize Blood Pressure For Clinical Effectiveness

Completed Results posted Last updated 19 December 2020

What this trial tests

trial testing Selara in Hypertension in 3,338 participants. Completed in 1 December 2012.

Timeline

1 June 2008

Primary endpoint
1 December 2012

1 December 2012

Quick facts

Lead sponsor	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,338
Start date	1 June 2008
Primary completion	1 December 2012
Estimated completion	1 December 2012

Drugs / interventions tested

Selara — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. — full company profile →

Who can join

Eligibility, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants With Treatment Related Adverse Events.
Time frame: 12 weeks
Adverse events mean all unfavorable events that occur in participants after administration of Selara, irrespective of causal relationship to Selara (including clinically problematic abnormal changes in laboratory test values). Treatment Related Adverse Events were evaluated in company with the causal relationship to Selara.
Number of Participants With Serious Treatment Related Adverse Events.
Time frame: 12 weeks
Serious treatment related adverse events mean those that may lead to death, life-threatening, hospitalization or prolonged hospitalization, a permanent or remarkable disorder/dysfunction, congenital anomaly/congenital deficiency, or other medically significant events or disorder.

Sponsor's own description

To collect the efficacy and safety information of Eplerenone on patients with hypertension related to their appropriate use in daily practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Pfizer's Upjohn has merged with Mylan to form Viatris Inc. trials

Trials by the same sponsor.

NCT04391868 — A Bioequivalence Study of Sildenafil Citrate Orally-Disintegrating Film Dosage Form · Phase 1 · withdrawn
NCT04176367 — An Bioequivalence Study Comparing Nicergoline 10 mg Tablet Manufactured in China With Nicergoline 10 mg Tablet Manufactu · Phase 1 · completed
NCT03768726 — Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents · Phase 3 · terminated
NCT03711708 — Relative Bioavailability Study of Zoloft Oral Solution to Zoloft Tablets · Phase 4 · completed
NCT03342690 — Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00749775 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Last refreshed: 19 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00749775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing